• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Friday 11/16/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Citius Pharmaceuticals

  • 2:04 PM

    Worldwide License for Mino-Lok™ is Now Complete CRANFORD, N.J., March 23, 2017, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.  South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center (“MDACC”), and

    Read more
  • 3:09 PM

    Manufacturing Finalized and Site Recruitment Initiated PR Newswire, CTXR CRANFORD, N.J., Dec. 8, 2016 CRANFORD, N.J., Dec. 8, 2016 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided details of its phase 3 trial for Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).  Mino-Lok is being developed as an adjunctive therapy for the treatment of

    Read more
  • 1:42 PM

    Site Recruitment is Underway CRANFORD, N.J., Sept. 13, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated the pivotal Phase 3 clinical trial Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or

    Read more
  • 7:26 PM

    Two Contract Manufacturing Organizations Engaged to Produce Clinical Trial Material PR Newswire CRANFORD, N.J., Sept. 8, 2016 CRANFORD, N.J., Sept. 8, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC QB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has initiated manufacturing for the company’s clinical trial of Mino-Lok ™, an antibiotic lock solution used to salvage central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs).

    Read more
  • 3:13 PM

    CRANFORD, N.J., Sept. 7, 2016, CTXR, /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC QB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that its Chairman, Len Mazur, will present at the Rodman & Renshaw 18th Annual Global Investment Conference. The Conference will be held on September 11-13, 2016 at the Lotte New York Palace Hotel, New York City. Event: Rodman & Renshaw 18th Annual Global Investment Conference Location:

    Read more
  • 4:42 PM

    CRANFORD, N.J., Aug. 23, 2016 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced completion of market research with in-depth interviews on patient-reported signs and symptoms of hemorrhoids and treatment outcomes with its Hydro-Lido product. Citius and the market research group conducted in-depth, in-person and telephonic interviews of patients who were diagnosed with grade II and grade III hemorrhoid disease. The interviews

    Read more
Public Wire Banner